Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Hudis

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Oncology (Williston Park, N.Y.)|March 1, 1997
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experienceA D Seidman, C A Hudis, G Raptis, et al.
Seminars in Oncology|October 1, 1995
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancerA D Seidman, C A Hudis, D Fennelly, et al.
Current Cancer Drug Targets|September 11, 2008
The heat shock protein 90 chaperone complex: an evolving therapeutic targetM F Barginear, C Van Poznak, N Rosen, et al.
Journal of Consulting and Clinical Psychology|February 1, 1995
Conditioned emotional distress in women receiving chemotherapy for breast cancerP B Jacobsen, D H Bovbjerg, M D Schwartz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1995
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancerT A DiLorenzo, P B Jacobsen, D H Bovbjerg, et al.
Seminars in Oncology|December 1, 1995
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodesC A Hudis, A D Seidman, J Baselga, et al.
Seminars in Oncology|November 28, 1997
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancerA D Seidman, C A Hudis, J McCaffrey, et al.
Oncogene|October 27, 2009
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthS Chandarlapaty, M Scaltriti, P Angelini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)K J Ruddy, B N Pitcher, L E Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancerA D Seidman, C A Hudis, J Albanell, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Oncology (Williston Park, N.Y.)|March 1, 1997
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experienceA D Seidman, C A Hudis, G Raptis, et al.
Seminars in Oncology|October 1, 1995
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancerA D Seidman, C A Hudis, D Fennelly, et al.
Current Cancer Drug Targets|September 11, 2008
The heat shock protein 90 chaperone complex: an evolving therapeutic targetM F Barginear, C Van Poznak, N Rosen, et al.
Journal of Consulting and Clinical Psychology|February 1, 1995
Conditioned emotional distress in women receiving chemotherapy for breast cancerP B Jacobsen, D H Bovbjerg, M D Schwartz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1995
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancerT A DiLorenzo, P B Jacobsen, D H Bovbjerg, et al.
Seminars in Oncology|December 1, 1995
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodesC A Hudis, A D Seidman, J Baselga, et al.
Seminars in Oncology|November 28, 1997
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancerA D Seidman, C A Hudis, J McCaffrey, et al.
Oncogene|October 27, 2009
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthS Chandarlapaty, M Scaltriti, P Angelini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)K J Ruddy, B N Pitcher, L E Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancerA D Seidman, C A Hudis, J Albanell, et al.
Pageof 5